ArticleClinical neuropsychiatry2026
Redox Imbalance in ADHD: A Meta-Analysis of Oxidative Stress and Antioxidant Biomarkers (2010-2025).
Article in Clinical neuropsychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Oxidative-antioxidant imbalance has been proposed as a biological contributor to attention-deficit/hyperactivity disorder (ADHD), yet findings across biomarkers, age groups and assay platforms remain heterogeneous. We synthesised evidence on oxidative damage markers (malondialdehyde [MDA], 8-hydroxy-2'-deoxyguanosine [8-OHdG]), global redox indices (total oxidant status [TOS], oxidative stress index [OSI], total antioxidant status [TAS]) and enzymatic antioxidants (superoxide dismutase [SOD], glutathione peroxidase [GPx], catalase [CAT]). Method: Following PRISMA 2020 guidelines, we searched major databases for studies published between 2010 and 2025. Case-control studies and baseline data from trials reporting group means and standard deviations were eligible. Standardised mean differences (Hedges' g) were pooled using random-effects models. Prespecified moderators included age group, medication status and assay or biological matrix. Results: Across fifteen case-control studies, ADHD was associated with a consistent shift towards oxidative imbalance. Oxidative damage was higher in ADHD for MDA (g = 0.32, 95% CI 0.18-0.46), 8-OHdG (g = 0.27, 0.10-0.44), TOS (g = 0.35, 0.20-0.50) and OSI (g = 0.31, 0.16-0.46). Antioxidant capacity was reduced for TAS (sign-inverted g = 0.25, 0.08-0.42) and SOD (sign-inverted g = 0.22, 0.05-0.39), whereas GPx and CAT showed no consistent differences. Heterogeneity was low to moderate, with no evidence of publication bias. Effects were larger in drug-naïve paediatric samples than in adults or treated cohorts. Conclusions: ADHD is associated with a small-to-moderate redox imbalance, most pronounced in untreated paediatric populations. These findings support oxidative-antioxidant dysregulation as a biologically meaningful dimension of ADHD and provide a framework for understanding heterogeneity in psychopharmacological response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.